J&J’s Risperdal Wasn’t Factor in Man’s Diabetes, Jury Rules
This article is for subscribers only.
Johnson & Johnson’s anti-psychotic drug Risperdal wasn’t a substantial factor in causing a Nebraska man’s diabetes, even though J&J failed to adequately warn his doctor about the drug’s risks, a New Jersey jury ruled.
Jurors in state court in New Brunswick, where J&J is based, today found by a 5-1 vote that the company didn’t adequately warn the doctor for Gary Skala of the risk of diabetes. Because they ruled 5-1 against Skala, 56, on the causation question, they didn’t award him any damages.